Comments
Jubilant Life Sciences on Friday reported a 19 per cent increase in consolidated net profit for the second quarter ended September 30, 2019 at ₹249 crore (₹210 crore).
Total revenue from operations for the quarter under review remained almost flat at ₹2,266 crore (₹2,269 crore).
Commenting on the company’s performance, Shyam Bhartia, Chairman, said, “We witnessed steady performance in revenue and improvement in operating profits in second quarter. Pharmaceutical segment revenues grew 9 per cent both in year-on-year and quarter-on-quarter, led by growth in all key businesses.”
In the Life Science Ingredients (LSI) segment, while the company witnessed good growth in Specialty Intermediates and Nutritional Products businesses, the overall revenue was down 15 per cent year-on-year due to lower input prices of acetic acid and higher molasses prices in the Life Sciences Chemical business, a company release said.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.